Everest Medicines Announces Close of Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib
Travere Therapeutics has closed the exclusive licensing agreement with Everest Medicines for civorebrutinib (EVER001), securing rights to the potential best-in-class BTK inhibitor in the U.S. and global markets excluding Greater China and parts of Asia. The transaction includes an upfront payment of $112.5 million from Travere to Everest, with additional potential milestone payments of up to $1.03 billion tied to clinical, regulatory, and commercial achievements.
Key figures
- Drug Name
- Civorebrutinib (EVER001)
- Deal Value Usd
- 112500000
- Royalties
- high single-digit to double-digit percentages
- Upfront payment
- $112.5 million
- Potential milestones
- $1.03 billion
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.